Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952443 | 0.88 | BRD4 (0.46) | RAB9ANPC1HDAC6RNASEH1GAA | |
| Maleic Acid SCHEMBL6948865 | 0.86 | RAB9A (0.41) | RAB9ANPC1HDAC6CHRM1RNASEH1 | |
| SCHEMBL7656006 | 0.86 | KDM4E (0.42) | RAB9ANPC1HDAC6RNASEH1GAA | |
| SCHEMBL29828622 | 0.86 | CHEK1 (0.48) | RAB9ANPC1HDAC6HTR6BRD4 | |
| SCHEMBL6945277 | 0.86 | CHEK1 (0.48) | RAB9ANPC1HDAC6HTR6BRD4 | |
| SCHEMBL6943101 | 0.85 | RAB9A (0.50) | RAB9ANPC1HDAC6CHRM1RNASEH1 | |
| SCHEMBL7649489 | 0.85 | NPC1 (0.41) | RAB9ANPC1HDAC6RNASEH1HTR6 | |
| SCHEMBL6953878 | 0.84 | RAB9A (0.49) | RAB9ANPC1HDAC6RNASEH1HTR6 | |
| SCHEMBL7650912 | 0.84 | NPC1 (0.40) | RAB9ANPC1HDAC6RNASEH1GAA | |
| SCHEMBL7653156 | 0.84 | ALDH1A1 (0.42) | RAB9ANPC1HDAC6RNASEH1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060158-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-04 | — | — | US | claimed |
| EP-3684410-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | Institut Curie (FR) | 2020-07-29 | — | — | EP | claimed |
| WO-2019057744-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | INSTITUT CURIE (FR) | 2019-03-28 | — | — | WO | claimed |
| US-20250236840-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2025-07-24 | — | — | US | disclosed |
| US-20230152314-A1 | LIPOCALIN-2 ASSAY FOR INTESTINAL ADAPTATION | THE JOHNS HOPKINS UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| US-20220275331-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2022-09-01 | — | — | US | disclosed |
| US-20210060158-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-04 | — | — | US | disclosed |
| EP-3684410-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | Institut Curie (FR) | 2020-07-29 | — | — | EP | disclosed |
| EP-2598138-B1 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | UNIV BOSTON (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-06-11 | — | — | US | disclosed |
| WO-2017072251-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2017-05-04 | — | — | WO | disclosed |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-06-23 | — | — | US | disclosed |
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2598138-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | Trustees of Boston University (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015914-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-0936218-B1 | BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6387938-B1 | Benzimidazole derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| WO-2001058877-A1 | INTERFERON Ω PRODUCTION POTENTIATORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-16 | — | — | WO | disclosed |
| EP-0936218-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | RAB9A 3842/4885NPC1 1683/4885HDAC6 1238/4885 |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | RAB9A 3842/4885NPC1 1683/4885HDAC6 1238/4885 |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | RORC, OXA1L, CX3CR1 | RAB9A 3183/4885NPC1 2300/4885HDAC6 141/4885 |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | AHR, ARNT, AIPL1 | RAB9A 3842/4885NPC1 1683/4885HDAC6 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.